Notably, the data showed that patients who responded well to the treatment had a higher median BRAFi Type I 1/2 MSS than those who did not respond, and this difference was almost significant despite the small sample size (Supplementary Fig.
← all excerpts
MAPK inhibitor sensitivity scores predict sensitivity driven by the immune infiltration in pediatric low-grade gliomas.
1
—
—